Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 490

1.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.

Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK.

Breast Cancer Res Treat. 2018 May 15. doi: 10.1007/s10549-018-4785-z. [Epub ahead of print]

PMID:
29766362
2.

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S.

Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15.

PMID:
29545334
3.

Corrigendum: Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.

Hazel P, Kroll SHB, Bondke A, Barbazanges M, Patel H, Fuchter MJ, Coombes RC, Ali S, Barrett AGM, Freemont PS.

ChemMedChem. 2018 Jan 22;13(2):207. doi: 10.1002/cmdc.201700826. Epub 2018 Jan 16. No abstract available.

PMID:
29372749
4.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

5.

p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.

Periyasamy M, Singh AK, Gemma C, Kranjec C, Farzan R, Leach DA, Navaratnam N, Pálinkás HL, Vértessy BG, Fenton TR, Doorbar J, Fuller-Pace F, Meek DW, Coombes RC, Buluwela L, Ali S.

Nucleic Acids Res. 2017 Nov 2;45(19):11056-11069. doi: 10.1093/nar/gkx721.

6.

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2017 Sep 8;7(1):74. doi: 10.1186/s13550-017-0323-y. No abstract available.

7.

IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.

Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM.

Breast Cancer Res Treat. 2017 Nov;166(2):527-539. doi: 10.1007/s10549-017-4427-x. Epub 2017 Aug 9.

8.

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC; IRIS trial participants.

Breast Cancer Res Treat. 2017 Sep;165(2):343-353. doi: 10.1007/s10549-017-4328-z. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2018 Jan;167(1):407.

9.

NY-ESO-1 expression in DCIS: A new predictor of good prognosis.

Coombes RC, Caballero OL, Shousha S, Ghaem-Maghami S, Woodley-Barker L, Wilhelm-Benartzi CS, Neville AM.

Oncoscience. 2017 Apr 28;4(3-4):33-40. doi: 10.18632/oncoscience.348. eCollection 2017 Mar.

10.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.

11.

Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Coombes RC, Lam EW, Hu Y, Yagüe E.

Breast Cancer Res Treat. 2017 Jun;163(3):461-474. doi: 10.1007/s10549-017-4202-z. Epub 2017 Mar 24. Erratum in: Breast Cancer Res Treat. 2018 Jan 5;:.

12.

Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.

Hazel P, Kroll SH, Bondke A, Barbazanges M, Patel H, Fuchter MJ, Coombes RC, Ali S, Barrett AG, Freemont PS.

ChemMedChem. 2017 Mar 7;12(5):372-380. doi: 10.1002/cmdc.201600535. Epub 2017 Feb 6. Erratum in: ChemMedChem. 2018 Jan 22;13(2):207.

13.

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.

Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, Goddard K, Shahin V, Woodley-Barker L, Rosales BM, Coombes RC, Stebbing J, Shaw JA.

Clin Chem. 2017 Feb;63(2):532-541. doi: 10.1373/clinchem.2016.261834. Epub 2016 Dec 9.

14.

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.

Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, Goddard KS, Hastings RK, Luo J, Ogle O, Woodley L, Ali S, Stebbing J, Coombes RC.

Clin Cancer Res. 2017 Jan 1;23(1):88-96. doi: 10.1158/1078-0432.CCR-16-0825. Epub 2016 Jun 22.

15.

Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, Magnani L, Győrffy B, Jones LJ, Fuller-Pace F, Shousha S, Buluwela L, Rakha EA, Ellis IO, Coombes RC, Ali S.

Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. Epub 2016 Jun 14.

16.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.

17.

Stratified, precision or personalised medicine? Cancer services in the 'real world' of a London hospital.

Day S, Coombes RC, McGrath-Lone L, Schoenborn C, Ward H.

Sociol Health Illn. 2017 Jan;39(1):143-158. doi: 10.1111/1467-9566.12457. Epub 2016 Jul 27.

18.

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.

Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM.

Eur J Cancer. 2016 Jun;60:146-53. doi: 10.1016/j.ejca.2016.03.001. Epub 2016 Apr 26.

PMID:
27125966
19.

New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM.

Amrania H, Drummond L, Coombes RC, Shousha S, Woodley-Barker L, Weir K, Hart W, Carter I, Phillips CC.

Faraday Discuss. 2016 Jun 23;187:539-53. doi: 10.1039/c5fd00150a.

20.

Spearhead Nanometric Field-Effect Transistor Sensors for Single-Cell Analysis.

Zhang Y, Clausmeyer J, Babakinejad B, Córdoba AL, Ali T, Shevchuk A, Takahashi Y, Novak P, Edwards C, Lab M, Gopal S, Chiappini C, Anand U, Magnani L, Coombes RC, Gorelik J, Matsue T, Schuhmann W, Klenerman D, Sviderskaya EV, Korchev Y.

ACS Nano. 2016 Mar 22;10(3):3214-3221. doi: 10.1021/acsnano.5b05211. Epub 2016 Feb 1.

21.

Bone marrow micrometastases in early breast cancer-30-year outcome.

Mansi J, Morden J, Bliss JM, Neville M, Coombes RC.

Br J Cancer. 2016 Feb 2;114(3):243-7. doi: 10.1038/bjc.2015.447. Epub 2016 Jan 14.

22.

Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.

Nguyen VT, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Győrffy B, Woodley L, Meira A, Patten DK, Vircillo V, Periyasamy M, Ali S, Frige G, Minucci S, Coombes RC, Magnani L.

Nat Commun. 2015 Nov 27;6:10044. doi: 10.1038/ncomms10044.

23.

MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.

Hu Y, Li K, Asaduzzaman M, Cuella R, Shi H, Raguz S, Coombes RC, Zhou Y, Yagüe E.

Oncol Rep. 2016 Feb;35(2):1170-8. doi: 10.3892/or.2015.4412. Epub 2015 Nov 12.

24.

APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, Russell R, Remenyi J, Ochocka AM, Thomas RS, Fuller-Pace F, Győrffy B, Caldas C, Navaratnam N, Carroll JS, Zwart W, Coombes RC, Magnani L, Buluwela L, Ali S.

Cell Rep. 2015 Oct 6;13(1):108-121. doi: 10.1016/j.celrep.2015.08.066. Epub 2015 Sep 24.

25.

SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C.

Clin Cancer Res. 2016 Jan 15;22(2):479-91. doi: 10.1158/1078-0432.CCR-14-3277. Epub 2015 Sep 14.

26.

Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.

Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S.

Oncotarget. 2015 Aug 28;6(25):21685-703.

27.

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.

Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, Page K, Guttery D, Primrose L, Fernandez Garcia D, Shaw J, Viola P, Green A, Nolan C, Ellis IO, Rakha EA, Shousha S, Lam EW, Győrffy B, Lupien M, Coombes RC.

Oncotarget. 2015 Sep 8;6(26):21878-91.

28.

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.

Faronato M, Nguyen VT, Patten DK, Lombardo Y, Steel JH, Patel N, Woodley L, Shousha S, Pruneri G, Coombes RC, Magnani L.

Oncotarget. 2015 Sep 8;6(26):22467-79.

29.

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC; PathIES Sub-Committee.

Ann Oncol. 2015 Sep;26(9):1890-7. doi: 10.1093/annonc/mdv242. Epub 2015 May 22.

PMID:
26002610
30.

Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance.

Adams C, Cazzanelli G, Rasul S, Hitchinson B, Hu Y, Coombes RC, Raguz S, Yagüe E.

Oncol Rep. 2015 Jul;34(1):415-22. doi: 10.3892/or.2015.3988. Epub 2015 May 19.

31.

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw JA.

Clin Chem. 2015 Jul;61(7):974-82. doi: 10.1373/clinchem.2015.238717. Epub 2015 May 15.

32.

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2015 Apr 30;5:30. doi: 10.1186/s13550-015-0103-5. eCollection 2015. Erratum in: EJNMMI Res. 2017 Sep 18;7(1):76. EJNMMI Res. 2017 Sep 8;7(1):74.

33.

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.

Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, Lam EW.

Oncogene. 2016 Feb 25;35(8):990-1002. doi: 10.1038/onc.2015.152. Epub 2015 May 11.

34.

Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis.

Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes RC, Harding SE, Lyon AR, Stebbing J.

Cell Death Dis. 2015 May 7;6:e1754. doi: 10.1038/cddis.2015.89.

35.

Drug testing in the patient: toward personalized cancer treatment.

Coombes RC.

Sci Transl Med. 2015 Apr 22;7(284):284ps10. doi: 10.1126/scitranslmed.aab1214.

PMID:
25904739
36.

Zinc isotopes: a novel approach to biomarkers of breast cancer?

Larner F, Shousha S, Coombes RC.

Biomark Med. 2015;9(4):379-82. doi: 10.2217/bmm.15.8. No abstract available.

37.

Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast.

Caballero OL, Shousha S, Zhao Q, Simpson AJG, Coombes RC, Neville AM.

Oncoscience. 2013 Dec 12;1(1):14-20. eCollection 2014.

38.

Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes.

Blighe K, Kenny L, Patel N, Guttery DS, Page K, Gronau JH, Golshani C, Stebbing J, Coombes RC, Shaw JA.

PLoS One. 2014 Dec 29;9(12):e115346. doi: 10.1371/journal.pone.0115346. eCollection 2014.

39.

Zinc isotopic compositions of breast cancer tissue.

Larner F, Woodley LN, Shousha S, Moyes A, Humphreys-Williams E, Strekopytov S, Halliday AN, Rehkämper M, Coombes RC.

Metallomics. 2015 Jan;7(1):112-7. doi: 10.1039/c4mt00260a. Epub 2014 Dec 9.

40.

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.

Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, Rghebi B, Primrose L, Shaw JA, Thompson AM, Bliss JM, Coombes RC.

Breast Cancer Res Treat. 2014 Dec;148(3):581-90. doi: 10.1007/s10549-014-3183-4. Epub 2014 Nov 14.

PMID:
25395314
41.

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.

Filipović A, Lombardo Y, Faronato M, Abrahams J, Aboagye E, Nguyen QD, d'Aqua BB, Ridley A, Green A, Rahka E, Ellis I, Recchi C, Przulj N, Sarajlić A, Alattia JR, Fraering P, Deonarain M, Coombes RC.

Breast Cancer Res Treat. 2014 Nov;148(2):455-62. doi: 10.1007/s10549-014-3119-z. Epub 2014 Sep 24. Erratum in: Breast Cancer Res Treat. 2014 Nov;148(2):463. Fronato, Monica [corrected to Faronato, Monica].

42.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
43.

Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC.

Breast Cancer Res. 2014 Jun 11;16(3):R62. doi: 10.1186/bcr3675.

44.

The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.

Stebbing J, Harding V, Urch CE, Kaier T, Schofield G, Flook M, Alifrangis C, Young AM, Shaw JA, Coombes RC, Krell J.

Future Oncol. 2014 Dec;10(16):2555-60. doi: 10.2217/FON.14.107.

45.

Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.

Elliott KM, Dent J, Stanczyk FZ, Woodley L, Coombes RC, Purohit A, Palmieri C.

Br J Surg. 2014 Jul;101(8):939-48. doi: 10.1002/bjs.9477. Epub 2014 Mar 31.

PMID:
24687409
46.

Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation.

Fraser SP, Ozerlat-Gunduz I, Brackenbury WJ, Fitzgerald EM, Campbell TM, Coombes RC, Djamgoz MB.

Philos Trans R Soc Lond B Biol Sci. 2014 Feb 3;369(1638):20130105. doi: 10.1098/rstb.2013.0105. Print 2014 Mar 19. Review.

47.

Ion transport and cancer: from initiation to metastasis.

Djamgoz MB, Coombes RC, Schwab A.

Philos Trans R Soc Lond B Biol Sci. 2014 Feb 3;369(1638):20130092. doi: 10.1098/rstb.2013.0092. Print 2014 Mar 19. No abstract available.

48.

Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.

Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M, Gustafsson JÅ.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1933-8. doi: 10.1073/pnas.1323719111. Epub 2014 Jan 21.

49.

SUMOylation inhibits FOXM1 activity and delays mitotic transition.

Myatt SS, Kongsema M, Man CW, Kelly DJ, Gomes AR, Khongkow P, Karunarathna U, Zona S, Langer JK, Dunsby CW, Coombes RC, French PM, Brosens JJ, Lam EW.

Oncogene. 2014 Aug 21;33(34):4316-29. doi: 10.1038/onc.2013.546. Epub 2013 Dec 23.

50.

The role of genes co-amplified with nicastrin in breast invasive carcinoma.

Sarajlić A, Filipović A, Janjić V, Coombes RC, Pržulj N.

Breast Cancer Res Treat. 2014 Jan;143(2):393-401. doi: 10.1007/s10549-013-2805-6. Epub 2013 Dec 13.

PMID:
24337538

Supplemental Content

Loading ...
Support Center